Neurotrauma Reports: Injection of Ghrelin (OXE-103) Improves Subacute Concussion Symptom Burden and Quality of Life
The manuscript on Oxeia’s pilot Phase IIa trial was recently published by Neurotrauma Reports.The results of the trial indicate that Oxeia’s drug, OXE103, is a promising first-in class treatment for post-concussion symptoms.